Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ZL-65 in Healthy Adults
NCT07757152Phase 1Recruiting
- Sponsor
- Zenitar
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZL-65 (2 arms), sponsored by Zenitar. Primary endpoint: Incidence of adverse events. Started Jul 2026; status: recruiting.
02
Drugs
ZL-65
Beyond the preview
Go deeper on NCT07757152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757152.